Research

Research of Interest

The Cutaneous Lymphoma Foundation is pleased to provide the following published research abstracts and reports to provide an outlook on cutaneous lymphoma research:

Industry Spotlight: Actelion Pharmaceuticals

Earlier this spring, CLF CEO, Susan Thornton was able to chat with two members of the Medical Affairs team at Actelion. Director Badri Rengarajan, MD and Associate Director Gaurav Sharma, Pharm.D, talked about two unique projects that were initiated over the last year. The PROv Study is a prospective, observational study that is currently open with plans to enroll 300 MF patients who will participate for a two-year timeframe. The goal of the study is to gather information about disease evolution, insights into treatment patterns, quality of life and other characteristics of the patient journey. The team also developed of a quality of life measurement tool for early stage disease which was a collaborative project that included input from many of you. Learn more about these two interesting projects in Susan’s interview.  


Industry Spotlight: miRagen Therapeutics

In the second of our Industry Spotlight series, CLF CEO Susan Thornton caught up with Dr. Paul Rubin, Executive Vice President of miRagen Therapeutics at the recent T-Cell Forum in San Francisco.  miRagen Therapeutics is a biotech company based in Boulder, Colorado that focuses on a specific cell mechanism of action called microRNA.   Watch Susan's interview with Dr. Rubin video. miRagen is currently conducting a Phase I clinical trial in cutaneous lymphoma, learn more at www.clinicaltrials.gov.


Industry Spotlight: Soligenix

CLF CEO, Susan Thornton had the chance to sit down with Dr Rick Straube, Senior VP and Chief Medical Officer of Soligenix, Inc. recently to talk about their clinical trial for treating early stage cutaneous lymphoma. The treatment process uses a new topical photosensitizing agent (synthetic hypericin) and fluorescent light. We invite you to view Susan's interview with Dr. Straube and share with us your thoughts on this new potential treatment.


Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials

Journal of the American Academy of Dermatology, February 2015, Volume 72, Issue 2, Pages 286–292, http://www.jaad.org


Novel Tumor Markers for CTCL Identified

OncoTherapy Network, February 3, 2015, www.oncotherapynetwork.com

To read abstract:

Interleukin-13 is over-expressed in cutaneous T-cell lymphoma cells and regulates their proliferation

Blood Journal, January 27, 2015, www.bloodjournal.org

English French German Italian Portuguese Russian Spanish

This is an automatic translation service and therefore the
Cutaneous Lymphoma Foundation is not responsible
for any potential translation inaccuracies.